MX2017002225A - Procedimiento para elaborar la forma cristalina a de lenalidomida. - Google Patents
Procedimiento para elaborar la forma cristalina a de lenalidomida.Info
- Publication number
- MX2017002225A MX2017002225A MX2017002225A MX2017002225A MX2017002225A MX 2017002225 A MX2017002225 A MX 2017002225A MX 2017002225 A MX2017002225 A MX 2017002225A MX 2017002225 A MX2017002225 A MX 2017002225A MX 2017002225 A MX2017002225 A MX 2017002225A
- Authority
- MX
- Mexico
- Prior art keywords
- lenalidomide
- making crystalline
- crystalline form
- dimethylacetamide
- dimethylformamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con un procedimiento para elaborar la forma A cristalina de lenalidomida de la fórmula (1), caracterizada por un patrón de difracción de polvo XRPD que comprende los picos en aproximadamente 7.89, 4.35, 14.83, 15.81, 16.23, 20.12, 23.78, 24.09, 25.96 grados 2 theta, cuando se miden con la radiación CuKa1 (? = 1.54060 ?), el procedimiento comprende: 1. reducción de 3-(4-nitro-1-oxo-1,3-dihidro-2H-isoindo l-2-iI)-2,6-piperidinadiona de la fórmula (2) con un agente reductor en un solvente mezclado que comprende una mezcla de alcohol alifático de C1-C3 y N,N-dimetilformamida o N,N-dimetilacetamida, en donde el contenido de N,N-dimetilformamida o N,N-dimetilacetamida en el solvente mezclado está entre 20 y 40 % (v/v), 2; aislamiento de la forma de lenalidomida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2014067637 | 2014-08-19 | ||
PCT/EP2015/068774 WO2016026785A1 (en) | 2014-08-19 | 2015-08-14 | Process for making crystalline form a of lenalidomide |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017002225A true MX2017002225A (es) | 2017-05-22 |
MX369968B MX369968B (es) | 2019-11-27 |
Family
ID=53835469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017002225A MX369968B (es) | 2014-08-19 | 2015-08-14 | Procedimiento para elaborar la forma cristalina a de lenalidomida. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3183244B1 (es) |
KR (1) | KR102516638B1 (es) |
ES (1) | ES2733813T3 (es) |
MX (1) | MX369968B (es) |
WO (1) | WO2016026785A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108658935A (zh) * | 2017-03-27 | 2018-10-16 | 天津大学 | 来那度胺新晶型、其制备方法及其医药用途 |
WO2019064222A1 (en) * | 2017-09-27 | 2019-04-04 | Biocon Limited | CRYSTALLINE FORMS OF LENALIDOMIDE |
EP3789385A4 (en) * | 2018-06-01 | 2021-06-16 | Shanghai Bocimed Pharmaceutical Co., Ltd. | METHOD FOR PRODUCING LENALIDOMIDE |
WO2022144924A1 (en) * | 2021-01-04 | 2022-07-07 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110021567A1 (en) * | 2008-03-11 | 2011-01-27 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
WO2010100476A2 (en) | 2009-03-02 | 2010-09-10 | Generics [Uk] Limited | Improved process |
AU2010290822A1 (en) * | 2009-09-03 | 2012-03-29 | Ranbaxy Laboratories Limited | Process for the preparation of lenalidomide |
LV14985B (lv) * | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
-
2015
- 2015-08-14 ES ES15749841T patent/ES2733813T3/es active Active
- 2015-08-14 EP EP15749841.1A patent/EP3183244B1/en active Active
- 2015-08-14 MX MX2017002225A patent/MX369968B/es active IP Right Grant
- 2015-08-14 KR KR1020177007407A patent/KR102516638B1/ko active IP Right Grant
- 2015-08-14 WO PCT/EP2015/068774 patent/WO2016026785A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP3183244A1 (en) | 2017-06-28 |
ES2733813T3 (es) | 2019-12-03 |
KR20170042765A (ko) | 2017-04-19 |
EP3183244B1 (en) | 2019-04-10 |
WO2016026785A1 (en) | 2016-02-25 |
KR102516638B1 (ko) | 2023-04-03 |
MX369968B (es) | 2019-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3675B1 (ar) | مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
MX2018003280A (es) | Proceso de compuesto antifungico. | |
MY196328A (en) | New (Hetero)Aryl-Substituted-Piperidinyl Derivatives, A Process For Their Preparation And Pharmaceutical Compositions Containing Them | |
PH12014000179A1 (en) | New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
PH12015502615A1 (en) | Chemical compounds | |
MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
MX2018012085A (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
EA033513B1 (ru) | Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
GEP201706671B (en) | Heterocyclyl compounds as mek inhibitors | |
NZ711192A (en) | Process for making benzoxazepin compounds | |
MX369968B (es) | Procedimiento para elaborar la forma cristalina a de lenalidomida. | |
EP3795578A3 (en) | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof | |
MX2016000900A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
IN2013MU03862A (es) | ||
PH12015502486A1 (en) | N-(2-fluoro-2-phenethyl)carboxamides as nematicides and endoparasiticides | |
IN2015DN00950A (es) | ||
MX350122B (es) | Tinturas dispersas, su preparación y su uso. | |
IN2014CH00304A (es) | ||
GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
MX2015008624A (es) | PROCESO PARA PREPARAR 6A, 14A-ETENOMORFINANOS 7ß SUSTITUIDOS Y 6A, 14A-ETANOMORFINANOS 7ß-SUSTITUIDOS. | |
MX2015012350A (es) | Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4. | |
RU2013140117A (ru) | Способ получения модифицированной серы | |
MX2016005222A (es) | Tinturas acidas, proceso para su produccion y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |